This suggested that strategies focused on enhancing the expression and/or activity of eEF1A2 in muscles may offer therapeutic benefits for DMD (duchenne muscular dystrophy) patients [49]. This evidence concerns the gene EEF1A2 and Duchenne muscular dystrophy.